Cue Biopharma
CUE
99 hedge funds and large institutions have $393M invested in Cue Biopharma in 2020 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 7 closing their positions.
357% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 7
117% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 18
112% more capital invested
Capital invested by funds: $185M → $393M (+$208M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
34% more funds holding
Funds holding: 74 → 99 (+25)
0.24% more ownership
Funds ownership: 1.64% → 1.88% (+0.24%)
15% less call options, than puts
Call options by funds: $1.29M | Put options by funds: $1.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$15.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$15.8M |
| 3 |
BlackRock
New York
|
+$14.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.91M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$8.53M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$5.84M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$4.31M |
| 4 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$3.86M |
| 5 |
CAG
Crestwood Advisors Group
Boston,
Massachusetts
|
-$3.83M |
CUE Hedge Fund Activity: Q2 2020 in Review
99 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2020, worth a combined $393M — up 112% from $185M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CUE positions and 7 closed out — a net gain of 25 holders — while 39 added to existing stakes and 18 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $15.9M. The largest seller was Mangrove Partners, exiting entirely with an estimated $8.53M sold.
- 99 institutional investors held Cue Biopharma (CUE) as of Q2 2020, up from 74 in Q1 2020.
- Funds reported $393M of Cue Biopharma stock for Q2 2020, up 112% quarter-over-quarter.
- 32 funds opened new Cue Biopharma positions in Q2 2020 and 7 closed out, a net change of +25 holders.
- The largest Cue Biopharma buyer in Q2 2020 was Woodline Partners, an estimated $15.9M added.
- The largest Cue Biopharma seller in Q2 2020 was Mangrove Partners, an estimated $8.53M sold.
Based on aggregated 13F filings for Q2 2020.